Pricing Log in Create free account
Friday 6 November 2026 Export BIIB’s income statement to Excel — free account

Biogen Inc.

BIIB Healthcare Drug Manufacturers General

Biogen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.9 billion, up 2.22% from fiscal 2024.

Revenue
+10.6%
EPS
−104.4%
Free cash flow
−69.3%
Total debt
+16.0%

Quarter to September 2026, against a year earlier

248.11 4.18 +1.71%
Market cap
$36.1B
P/E
104×
Fwd P/E
47.4×
Dividend yield
—
F-score
4/9
Altman Z
3.13
Beneish M
−2.67
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Biogen Inc. (BIIB) revenue by segment, product and region

Annual Quarterly
Download Excel — free account

Where the money comes from and where it goes

Fiscal 2025: revenue by segment, and margins
Reportable Segment 9,891 100.00%
Gross margin 75.69%
Operating margin 18.83%
Pre-tax margin 15.74%

Revenue by segment $m

Line FY2025 FY2024 FY2023 FY2022
Reportable Segment 9,891 9,676 9,836 10,173
Revenue 9,891 9,676 9,836 10,173

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.